Alessandra Giuliano1,
Francesca Mandreucci1,
,
Alida Benfante2,
Maria Noemi Cicero2,
Gabriele Seminara2,
Nicola Scichilone2,
Antonio Carroccio1,
Erica Maria Bruno3,
Daniele Castellucci3,
Marta Chiavetta3,
Stella Compagnoni3,
Noemi Monachino3,
Giulia Teresi3,
Giuseppe Martorana3,
Simonetta Maisano3 1Internal Medicine Unit, V. Cervello Hospital, Palermo, Italy;
2Pulmonology Unit, AOUP Paolo Giaccone Hospital, Palermo, Italy
3The Internal Medicine Unit Study Group (IMUSG)
American Journal of Medical Case Reports.
2021,
Vol. 9 No. 9, 482-484
DOI: 10.12691/ajmcr-9-9-10
Copyright © 2021 Science and Education PublishingCite this paper: Alessandra Giuliano, Francesca Mandreucci, Alida Benfante, Maria Noemi Cicero, Gabriele Seminara, Nicola Scichilone, Antonio Carroccio, Erica Maria Bruno, Daniele Castellucci, Marta Chiavetta, Stella Compagnoni, Noemi Monachino, Giulia Teresi, Giuseppe Martorana, Simonetta Maisano. Resolution of Chronic Eosinophilic Pneumonia during Treatment with Benralizumab in Patient with Peripheric Blood Eosinophilia.
American Journal of Medical Case Reports. 2021; 9(9):482-484. doi: 10.12691/ajmcr-9-9-10.
Correspondence to: Francesca Mandreucci, Internal Medicine Unit, V. Cervello Hospital, Palermo, Italy;. Email:
francesca.mandreucci@gmail.comAbstract
Chronic eosinophilic pneumonia is a rare idiopathic form of pneumonia. A differential diagnosis is crucial to distinguish idiopathic from secondary forms and it requires clinical, laboratory and imaging investigations. In this case report we present a case of Chronic eosinophilic pneumonia and discuss differential diagnosis in a patient with a history of uncontrolled chronic asthma and moderate peripheral eosinophilia. Benralizumab, an anti-Interleukin-5 receptor drug, was administered to our patient, who remained asymptomatic throughout a ten-month follow-up. Further studies are essential to confirm the favorable effect of this novel therapy for Chronic eosinophilic pneumonia.
Keywords